Rapid Micro Biosystems, Inc. filed a Form 8-K on November 16, 2026, reporting its financial results for the third quarter ended September 30, 2026, and disclosing a pending tender offer by Merck KGaA, Darmstadt, Germany.

Key Highlights

  • Q3 2026 results announced: The company issued a press release on November 16, 2026, announcing financial results for the quarter ended September 30, 2026.
  • Pending acquisition disclosed: Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. are described in the filing as parties to a proposed tender offer for Rapid Micro Biosystems shares.
  • Tender offer not yet commenced: According to the filing, the tender offer had not yet commenced as of the report date.
  • Schedule TO and 14D-9 filings anticipated: The filing states that Merck KGaA and Purchaser will file a tender offer statement on Schedule TO, and Rapid will file a solicitation/recommendation statement on Schedule 14D-9, with the SEC.
  • Emerging growth company status: The registrant indicated it is an emerging growth company as defined under applicable securities regulations.
  • Exhibit 99.1 attached: A copy of the press release containing the financial results is attached as Exhibit 99.1 to the filing.

Rapid Micro Biosystems Discloses Q3 Results and Proposed Merck KGaA Acquisition

Rapid Micro Biosystems, Inc. (NASDAQ:RPID), headquartered at 25 Hartwell Avenue, Lexington, Massachusetts, filed a current report on November 16, 2026, covering its third-quarter financial results and a proposed acquisition. The company, which describes itself as a provider of automated microbial quality control testing, attached a press release as Exhibit 99.1 containing the Q3 2026 financial details. The filing was made under Item 2.02, covering results of operations and financial condition, and the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as the filing explicitly states.

The 8-K also discloses that Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. are parties to a proposed tender offer to acquire Rapid Micro Biosystems shares, though the filing states the tender offer had not yet commenced as of the report date. The filing notes that a merger agreement is in place, and that closing conditions must be satisfied for the acquisition to proceed. Risks cited in the filing include the possibility that closing conditions will not be met, uncertainty about stockholder participation, potential stockholder litigation, and the risk that the offer may not be completed in the expected timeframe or at all.

The filing contains forward-looking statements, which the company identifies as subject to known and unknown risks and uncertainties. These include risks related to the company's ability to achieve positive cash flow, fulfill customer orders, maintain its manufacturing facility, and improve gross margins. The company states it has no obligation to update forward-looking statements except as may be required by law.

What Was Disclosed

Rapid Micro Biosystems filed an 8-K on November 16, 2026, reporting Q3 2026 results via an attached press release and disclosing a proposed but not yet commenced tender offer by Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc.